Full-Time

Senior Production Operator

Healthcare

Posted on 7/4/2025

Dexcom

Dexcom

5,001-10,000 employees

Develops continuous glucose monitoring systems

No salary listed

Mid, Senior

Minna, Inverin, Co. Galway, Ireland

In Person

Category
Diagnostics & Laboratory Professionals
Medical, Clinical & Veterinary
Requirements
  • High level of dexterity and attention to detail is essential
  • Must be eligible to work in Ireland
  • Be punctual, complete task efficiently
  • Ability to work on complex tasks
Responsibilities
  • Cross trained on multiple processes at Dexcom
  • Recognized as a Subject Matter Expert in key areas
  • Compliance to all quality procedures; flag if any deviation noted
  • Completion and maintenance of quality documentation as required for the manufacture of Medical devices (GMP requirements)
  • Comply with all safety requirements and operate in a safe manner
  • Compete task to predefined deliverables/targets as assigned by your supervisor
  • Set up and operates a variety of automatic or semi-automatic machines including robotic assembly equipment used in the production of the company's product
  • Responsible for the overall operation of manufacturing machinery including actions such as feeding materials for processing, adjusting settings, performing minor repairs, applying labels, packaging, moving raw materials and finished product, and data entry
  • Can be deployed as a trainer for other employees
  • Checks and inspects product as required against required specifications
  • As part of a team ensure communications are clear and courteous
Desired Qualifications
  • 4 to 6 years Medical device and cleanroom experience
  • Demonstrated computer literacy
  • Mechanically minded
  • Working in a team
  • Communication skills
  • Training/knowledge transfer skills required

Dexcom develops and sells continuous glucose monitoring (CGM) systems designed to help individuals manage diabetes. The main product, the Dexcom G6 CGM System, provides users with real-time glucose readings, enabling better management of their condition. The system includes a sensor that is placed under the skin to measure glucose levels continuously, and the data is sent to a smartphone or receiver for easy access. Dexcom differentiates itself from competitors by offering a user-friendly interface and advanced data analytics through its Dexcom CLARITY software, which helps users and healthcare providers make informed decisions based on glucose trends. The company's goal is to enhance the quality of life for diabetes patients by providing accurate and convenient glucose monitoring solutions.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1999

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA clearance of Dexcom G7 enhances product credibility and market reach.
  • Integration with Nanowear's SimpleSense expands Dexcom's technological ecosystem.
  • Hiring 1000 skilled workers indicates growth and investment in innovation.

What critics are saying

  • Investigation by Johnson Fistel may affect investor confidence and lead to legal challenges.
  • Glu-Chek's competitive sensor technology could impact Dexcom's market share.
  • Data privacy concerns with Nanowear integration may pose security challenges.

What makes Dexcom unique

  • Dexcom G7 offers a 15-day wear period, reducing sensor replacements and waste.
  • Direct Apple Watch connectivity allows users to view glucose levels without an iPhone.
  • Dexcom CLARITY app provides interactive reports for glucose patterns and trends.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Remote Work Options

Flexible Work Hours

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Business Wire
Jun 10th, 2025
Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders

SAN DIEGO-(BUSINESS WIRE)-Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws.

GluChek
May 18th, 2025
Why Glu-Chek Sensors Compete with the Best in the World

Among the top players, Glu-Chek has emerged as a strong global competitor - offering sensor technology that rivals industry leaders like Dexcom and FreeStyle Libre.

Our Health Needs
Apr 14th, 2025
Dexcom receives FDA clearance for G7 15 Day glucose monitoring system

In March, cardiometabolic digital diagnostics company Nanowear announced a licensing and data partnership with Dexcom to integrate glucose data from the Dexcom G7 into its SimpleSense nanotechnology-enabled wearable.

Hit Consultant
Apr 10th, 2025
Fda Clears Dexcom G7 15 Day Continuous Glucose Monitoring System

What You Should Know:– Dexcom, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for individuals over the age of 18 with diabetes.– The Dexcom G7 15 Day system boasts an overall Mean Absolute Relative Difference (MARD) of 8.0% and builds upon the proven performance of Dexcom CGM technology, which has been clinically demonstrated to lower A1C, reduce hyper- and hypoglycemia, and increase time in range.Dexcom G7 FeaturesThe Dexcom G7 15 Day system offers up to 15.5 days of wear allowing users to benefit from fewer monthly sensors and reduced monthly waste. The waterproof CGM system provides an overall MARD of 8.0%.Other key features of Dexcom G7 include:Apple Watch Connectivity: Direct sensor connection to Apple Watch, allowing users to view glucose numbers without their iPhone.Direct sensor connection to Apple Watch, allowing users to view glucose numbers without their iPhone. Automated Logging: Automated activity logging, simplified meal logging, and new medication logging to help users understand the impact of these factors on glucose levels.Automated activity logging, simplified meal logging, and new medication logging to help users understand the impact of these factors on glucose levels. 12-Hour Grace Period: A 12-hour grace period for sensor replacement, ensuring a smoother transition between sessions.A 12-hour grace period for sensor replacement, ensuring a smoother transition between sessions. Mobile App with Dexcom Clarity: An innovative and user-friendly mobile app with Dexcom Clarity integration for easy viewing of glucose patterns, trends, and statistics through interactive reports.An innovative and user-friendly mobile app with Dexcom Clarity integration for easy viewing of glucose patterns, trends, and statistics through interactive reports

wflqzhanghaoran
Mar 27th, 2025
Dexcom COO on 15-day glucose sensor, Type 2 coverage | MedTech Dive

Dexcom is preparing to launch a 15-day version of its G7 continuous glucose monitor, based on data presented Thursday at the Advanced Technologies & Treatments for Diabetes conference.

INACTIVE